GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (STU:ZR8) » Definitions » Goodwill-to-Asset

Oncodesign Precision Medicine (STU:ZR8) Goodwill-to-Asset : 0.00 (As of Jun. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Oncodesign Precision Medicine's Goodwill for the quarter that ended in Jun. 2022 was €0.00 Mil. Oncodesign Precision Medicine's Total Assets for the quarter that ended in Jun. 2022 was €4.72 Mil. Therefore, Oncodesign Precision Medicine's Goodwill to Asset Ratio for the quarter that ended in Jun. 2022 was 0.00.


Oncodesign Precision Medicine Goodwill-to-Asset Historical Data

The historical data trend for Oncodesign Precision Medicine's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Goodwill-to-Asset Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
Goodwill-to-Asset
- -

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22
Goodwill-to-Asset - - -

Competitive Comparison of Oncodesign Precision Medicine's Goodwill-to-Asset

For the Biotechnology subindustry, Oncodesign Precision Medicine's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncodesign Precision Medicine's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Goodwill-to-Asset falls into.



Oncodesign Precision Medicine Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Oncodesign Precision Medicine's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Goodwill to Asset (A: Dec. 2021 )=Goodwill/Total Assets
=0/8.372
=0.00

Oncodesign Precision Medicine's Goodwill to Asset Ratio for the quarter that ended in Jun. 2022 is calculated as

Goodwill to Asset (Q: Jun. 2022 )=Goodwill/Total Assets
=0/4.722
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncodesign Precision Medicine  (STU:ZR8) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Oncodesign Precision Medicine Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncodesign Precision Medicine (STU:ZR8) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (STU:ZR8) Headlines

No Headlines